At the end of 2024, we initiated the expansion portion of our trial in patients with TNBC, who have previously been treated with at least one topo-1 ADC, a population with a very high unmet need.
Adding to the volatility is the company's leveraged balance sheet. It completed its acquisition ... The company's acquisitions of Topo Chico (sparkling water) and Fairlife (high protein, low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback